Helsinn is committed to raising awareness of the importance of antiemetic guidelines. In synch with the #MASCC24 annual meeting, Helsinn reminds HCPs that MASCC/ESMO released new antiemetic guidelines. Key practice changing updates include recommended use of a triple combination of a NK1 receptor antagonist (RA), 5-HT3 RA and steroids prophylactically in situations where emetogenic potential is now considered at the high end of the moderate category (eg, for patients receiving carboplatin (AUC ≥ 5), for women <50 receiving oxaliplatin, for patients receiving ADCs such as trastuzumab-deruxtecan and sacituzumab-govitecan). #supportivecare #antiemetics #CINV
Helsinn Group’s Post
More Relevant Posts
-
This observational study by Hoisnard, et al. used the French SNDS database to compare the risk of gastrointestinal perforation (GIP) between JAKi and adalimumab in patients with RA, PsA or axSpA. All patients were ≥15 years old with at least one dispensation of a JAKi from 1 July 2017 to 31 December 2021. While the crude incidence rate of GIP was higher for JAKi than for adalimumab, there was no significant difference when data were adjusted for variables. You can find the full summary slide deck on the IMID Forum completely free along with the latest updates in #axSpA https://ow.ly/VGiK50S1UYN
-
-
MD, PhD. Dermatologist - Centro Hospitalar Universitário do Porto | Professor of Dermatology - University of Porto | Head of Clinical Trials Unit CAC-ICBAS/CHP | Instituto Médico de Estudos Imunológicos
Psoriasis Headline News from #EADV2024 Results from the Phase 2 OLE Study of ESK-001, an oral TYK2 inhibitor for the treatment of psoriasis, presented at the Late Breaking session, showed dose-dependent sustained increases in PASI endpoint responses observed over time, with the majority of patients (93% as observed, 82.7% using modified non-responder imputation) achieving PASI 75, the primary endpoint, at the highest dose of 40 mg twice daily. ESK-001 continued to show a favorable safety profile in the OLE. ESK-001 is an oral TYK2 inhibitor currently being evaluated in the Phase 3 ONWARD clinical program for the treatment of psoriasis. #EADV2024 #LateBreaking #ESK001
-
-
Van den Bosch, et al. present the 1-year results of their Phase 3 trial investigating the efficacy of upadacitinib in nr-axSpA. They found that treatment with upadacitinib showed sustained efficacy versus placebo with no new safety findings identified through 1 year of treatment. You can find the full summary on the IMID Forum completely free along with the latest updates in #AxialSpondyloarthritis https://ow.ly/URks50Srx10
-
-
Dear Colleagues, We invite you to explore a recent publication in the American Journal of Case Reports by authors from the Bach Mai Hospital, Hanoi, Vietnam, that highlights the serious effects of amlodipine-atenolol overdose and the challenges it poses in emergency patient management. This report describes a 64-year-old man who presented with hypotension, bradycardia, and severe metabolic acidosis after an overdose of the fixed drug combination. The successful treatment approach involved intravenous calcium chloride infusion, hyperinsulinemia euglycemia therapy, and continuous veno-venous hemodialysis. This case emphasizes the importance of timely and aggressive management in preventing cardiovascular collapse and metabolic acidosis. The complete report is now available on the American Journal of Case Reports webpage. | https://lnkd.in/gs7UdcgX
-
DoseMeRx’s new Vancomycin Hemodialysis model enhances our users’ ability to dose patients receiving intravenous #vancomycin & intermittent #hemodialysis. This Vancomycin Hemodialysis model applies to a diverse patient population & includes an additional clearance parameter to allow for an accurate reflection of vancomycin clearance during hemodialysis. The model was specifically developed to improve dosing calculations & therapeutic outcomes. View our full suite of clinically validated vancomycin models here: https://lnkd.in/gYASD3SY
-
-
At #GI24, new results from the LEAP-002 study's 12 month follow-up show that #lenvatinib monotherapy for HCC may provide a higher median OS rate than lenvatinib plus #pembrolizumab. Learn more: #HepatocellularCarcinoma
-
Here's the IDDSI Quote of the Week. For more info on IDDSI, visit Roche Dietitian’s Ultimate Guide to IDDSI: https://lnkd.in/gmUuhaq IDDSI #dysphagia #traininganddevelopment #nutritionauthority
-
-
SDNP is a Nonprofit Society that is the Home for all Dermatology Nurse Practitioners.
👏Today, we're spotlighting Blueprint Medicines. We're looking forward to stopping by your table to learn more about the treatment of systemic mastocytosis! #2024SDNPConference #SDNPKiawah2024 #DermCertified #DCNP #SDNP #CoreComptencies #DERMNP #DERMPA #DERM
-
-
Overall survival rate improved with the addition of pembrolizumab. #lungcancermatters #accesstotreatmentisaccesstolife http://prac.co/l/2yp25qxp
Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for Early-Stage NSCLC
practiceupdate.com
-
Get a better understanding of our innovative approaches to addressing shortcomings of existing therapies with our new website. Take a look at our pipelines here: https://bit.ly/3Q0dnhm #PALI #InflammatoryBowelDisease #IBD #CrohnsDisease #PrecisionMedicine
-
